Physician profile
John David Nuschke
NPI 1083665087
$2,079.66
in general payments reported to CMS, 2019-2025
21 companies · $572 in 2025
The $572 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $358 · 2020: $121 · 2021: $62.51 · 2022: $218 · 2023: $289 · 2024: $460 · 2025: $572.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,320.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,319.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $394.40 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $233.62 | 2019-2025 | |
| Amgen INC. | $219.52 | 2019-2025 | Evenity, Prolia, Otezla |
| Astrazeneca Pharmaceuticals LP | $213.06 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $166.38 | 2021-2025 | |
| Lilly USA, LLC | $154.61 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Exact Sciences Corporation | $84.73 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $84.16 | 2019-2025 | Shingrix, Arexvy |
| Janssen Pharmaceuticals, INC | $76.30 | 2019 | |
| Merck Sharp & Dohme LLC | $71.14 | 2020-2025 | Capvaxive, Gardasil 9, Gardasil |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $55.88 | 2019-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.27 | 2019-2020 | |
| Verona Pharma, INC. | $45.02 | 2025 | Ohtuvayre |
| Digital Diagnostics INC. | $39.00 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $35.48 | 2023-2024 | Eliquis |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $34.99 | 2025 | Rexulti |
| Viatris Specialty LLC | $30.93 | 2025 | Yupelri |
| Scilex Pharmaceuticals INC. | $24.92 | 2022 | |
| Novartis Pharmaceuticals Corporation | $24.75 | 2022 | |
| Philips North America LLC | $21.50 | 2023 | |
| Genentech USA, INC. | $15.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Nuschke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.